Description
Diridavumab, the alternative names CR6261, is a human monoclonal antibody direct against influenza A hemagglutinin. The CR6261 antibody was first discovered by the Scripps Institute and Crucell, a dutch biopharmaceutical company, and later developed by Janssen Pharmaceutical Companies of Johnson & Johnson under the trade name diridavumab. Cr6261 is under investigation in clinical trial NCT02016066 (A Study to Assess the Safety, Pharmacokinetics and Immunogenicity of Diridavumab in Japanese Healthy Participants).
Catalog No.
DVV03801
Host species
Homo sapiens
Species reactivity
Influenza A virus
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Concentration
2.76 mg/ml
Purity
>95% by SDS-PAGE.
Clonality
Monoclonal
Isotype
IgG1, lambda
Applications
Research Grade Biosimilar
Target
HA/Hemagglutinin
Purification
Protein A or G purified from cell culture supernatant.
Endotoxin level
Please contact with the lab for this information.
Expression system
XtenCHO
Accession
P03455
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.Store at +4°C short term (1-2 weeks).Store at -20 °C 12 months. Store at -80°C long term.
Alternative Names
CR-6261, CR6261, CAS: 1393659-46-5, Influenza Virus (Flu)
Note
For research use only. Not suitable for clinical or therapeutic use.
關(guān)鍵字： Diridavumab;HA/Hemagglutinin;
武漢佰樂博生物（Biolab Reagents）始創(chuàng)于 2021 年，核心創(chuàng)始團隊由五位畢業(yè)于武漢大學(xué)、華中科技大學(xué)、華中農(nóng)業(yè)大學(xué)等高校的生命科學(xué)領(lǐng)域資深研究者組成，團隊深耕行業(yè)二十載，積淀了扎實的產(chǎn)品開發(fā)實力與技術(shù)應(yīng)用經(jīng)驗，筑牢企業(yè)核心技術(shù)根基。
公司是國家高新技術(shù)企業(yè)、國家科技型中小企業(yè)，國家創(chuàng)新型中小企業(yè)，技術(shù)實力獲權(quán)威認可，還通過 ISO9001、ISO13485 雙質(zhì)量管理體系認證，以標準化品控筑牢產(chǎn)品品質(zhì)。依托全球領(lǐng)先技術(shù)平臺，公司專注高品質(zhì)生物試劑的全球化開發(fā)與整合，是法國 AntibodySystem 亞洲獨家授權(quán)合作伙伴以及生工生物KleanAB品牌的合作伙伴，現(xiàn)構(gòu)建起近 60000 種試劑的產(chǎn)品矩陣，核心涵蓋蛋白、抗體、試劑盒，重點覆蓋腫瘤、神經(jīng)系統(tǒng)，病原菌感染等疾病研究領(lǐng)域，滿足多元科研需求。
自成立以來，佰樂博生物始終為科研工作者、生物醫(yī)藥工業(yè)客戶提供專業(yè)的產(chǎn)品與技術(shù)支持，以優(yōu)質(zhì)科研工具賦能科研，助力生命科學(xué)研究創(chuàng)新發(fā)展、深度突破。